These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23457368)

  • 1. Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions.
    Pasipanodya JG; Gumbo T
    Am J Respir Crit Care Med; 2013 Mar; 187(5):554-5. PubMed ID: 23457368
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions.
    Koh WJ; Jeong BH; Jeon K; Lee SY; Shin SJ
    Am J Respir Crit Care Med; 2013 Mar; 187(5):555-6. PubMed ID: 23577353
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of pulmonary Mycobacterium avium complex infections: do drug levels matter?
    Schluger NW
    Am J Respir Crit Care Med; 2012 Oct; 186(8):710-1. PubMed ID: 23071188
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.
    Koh WJ; Jeong BH; Jeon K; Lee SY; Shin SJ
    Am J Respir Crit Care Med; 2012 Oct; 186(8):797-802. PubMed ID: 22878282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
    Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
    J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pulmonary disease caused by Mycobacterium avium complex.
    Shimokata K
    Intern Med; 2003 Aug; 42(8):627-8. PubMed ID: 12924480
    [No Abstract]   [Full Text] [Related]  

  • 7. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study.
    Hosono Y; Kitada S; Yano Y; Mori M; Miki K; Miki M; Yoshimura K; Kagawa H; Oshitani Y; Yokota S
    J Infect Chemother; 2018 May; 24(5):353-357. PubMed ID: 29361415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Embrace simplicity when treating lady windermere.
    Jarand J; Field SK
    Chest; 2014 Aug; 146(2):244-246. PubMed ID: 25091749
    [No Abstract]   [Full Text] [Related]  

  • 9. Clarithromycin treatment for Mycobacterium avium-intracellulare complex lung disease.
    Frothingham R
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1990-1. PubMed ID: 8665069
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis.
    Komiya K; Kurashima A; Ihi T; Nagai H; Matsumoto N; Mizunoe S; Ishii H; Takahashi O; Ohta K; Kudoh S; Kadota J
    Int J Antimicrob Agents; 2014 Aug; 44(2):131-5. PubMed ID: 24948577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility testing of Mycobacterium avium complex isolates.
    Heifets L
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1759-67. PubMed ID: 8843278
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.
    Koh WJ; Jeong BH; Jeon K; Park HY; Kim SY; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4994-6. PubMed ID: 25987622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and treatment history of clarithromycin resistance in M. avium-intracellulare complex pulmonary disease patients].
    Kuwabara K; Tsuchiya T
    Nihon Kokyuki Gakkai Zasshi; 2007 Aug; 45(8):587-92. PubMed ID: 17763685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
    Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
    BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease.
    Kim EY; Chi SY; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC; Kwon YS
    Korean J Intern Med; 2011 Mar; 26(1):54-9. PubMed ID: 21437163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.
    Carter G; Young LS; Bermudez LE
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4907-10. PubMed ID: 15561879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study.
    Kadota JI; Kurashima A; Suzuki K
    J Infect Chemother; 2017 May; 23(5):293-300. PubMed ID: 28254517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium avium complex lung disease and panhypopituitarism.
    Koh WJ; Kwon OJ
    Mayo Clin Proc; 2005 Jul; 80(7):961-2. PubMed ID: 16007905
    [No Abstract]   [Full Text] [Related]  

  • 19. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis.
    Wallace RJ; Zhang Y; Brown-Elliott BA; Yakrus MA; Wilson RW; Mann L; Couch L; Girard WM; Griffith DE
    J Infect Dis; 2002 Jul; 186(2):266-73. PubMed ID: 12134265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.
    Griffith DE; Brown BA; Cegielski P; Murphy DT; Wallace RJ
    Clin Infect Dis; 2000 Feb; 30(2):288-92. PubMed ID: 10671330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.